Clinical Trials Directory

Trials / Unknown

UnknownNCT05868317

Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer

Induction Chemotherapy With FOLFIRINOX ( 5 Fluorouracil, Oxaliplatine and Irinotecan) Followed by Short Course Radiotherapy in Locally Advanced Rectal Cancer

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
70 (estimated)
Sponsor
Salah Azaïz Cancer Institute · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

A Single-arm phase II trial evaluating induction chemotherapy with FOLFIRINOXm followed by short course radiotherapy (RT) in locally advanced rectal carcinoma

Detailed description

Total neoadjuvant treatment (TNT) is currently the standard of care in the management of locally advanced rectal cancer since recent studies have shown improved pathological complete response and disease-free survival with this approach. However, survival benefits remain unproven. Two strategies of TNT are validated so far : induction chemotherapy with FOLFIRINOX followed by long course radio-chemotherapy (RCT) or short course RT (5x5 Gy) followed by consolidation chemotherapy with CAPOX (capecitabine and oxaliplatin) or FOLFOX (5 FU and oxaliplatin) . The objective of investigators is to evaluate pathological complete response with a new strategy of TNT consisting in induction chemotherapy with FOLFIRINOXm followed by short course RT and a delayed surgery.

Conditions

Interventions

TypeNameDescription
DRUGChemotherapy With FOLFIRINOX ( 5 Fluorouracil, Oxaliplatine and Irinotecan)Induction chemotherapy with six cycles of modified 5 fluorouracil,oxaliplatin and irinotecan followed by short course radiotherapy (RT) (5x5 Gy), then two cycles of 5 fluorouracil and oxaliplatin based chemotherapy and surgery will be performed 6 to 8 weeks after completion of RT. After surgery , continuation of chemotherapy with 4 cycles of 5 fluorouracil and oxaliplatin regardless of pathological response
RADIATIONRadiotherapyShort Course Radiotherapy

Timeline

Start date
2020-11-01
Primary completion
2022-11-30
Completion
2023-11-30
First posted
2023-05-22
Last updated
2023-05-22

Locations

1 site across 1 country: Tunisia

Source: ClinicalTrials.gov record NCT05868317. Inclusion in this directory is not an endorsement.